Seagen
SGEN
$228.74
Share price
-0.07%
Change (1 day)
68.92%
Change (1 year)
Categories
P/S ratio for Seagen (SGEN)
P/S ratio as of April 2024 (TTM): 18.8
According to Seagen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 18.7601. At the end of 2023 the company had a P/S ratio of 17.3.
P/S ratio history for Seagen from 2002 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 17.3 | 42.37% |
| 2022 | 12.2 | -32.29% |
| 2021 | 18.0 | 24.61% |
| 2020 | 14.4 | -32.78% |
| 2019 | 21.4 | 54.56% |
| 2018 | 13.9 | -13.14% |
| 2017 | 16.0 | -10.62% |
| 2016 | 17.9 | -4.02% |
| 2015 | 18.6 | 33.99% |
| 2014 | 13.9 | -23.53% |
| 2013 | 18.2 | 38.06% |
| 2012 | 13.2 | -35.13% |
| 2011 | 20.3 | 43.5% |
| 2010 | 14.1 | -28.11% |
| 2009 | 19.7 | -9.49% |
| 2008 | 21.7 | -36.73% |
| 2007 | 34.3 | 26.3% |
| 2006 | 27.2 | 32.6% |
| 2005 | 20.5 | -49.89% |
| 2004 | 40.9 | -24.52% |
| 2003 | 54.2 | -4.09% |
| 2002 | 56.5 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.54 | -86.44% | 🇺🇸 USA |
 AbbVie ABBV | 5.47 | -70.84% | 🇺🇸 USA |
 Biogen BIIB | 2.99 | -84.05% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.20 | -88.27% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.21 | -88.23% | 🇬🇧 UK |
 Spectrum Pharmaceuticals
SPPI | 8.22 | -56.20% | 🇺🇸 USA |
 ImmunoGen
IMGN | 30.3 | 61.69% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 353 | 1,783.56% | 🇺🇸 USA |